Status:
UNKNOWN
An Epidemiological Study to Investigate the Characteristics of RSV Infection in Adult Hematopoietic Cell Transplant Recipients or Hematological Malignancies Patients in Tianjin HI (Hematology Institute)
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Conditions:
RSV Infection
Eligibility:
All Genders
18+ years
Brief Summary
This primary objective of this study is to describe the incidence of RSV infection in adult hematopoietic cell transplant recipients OR hematological malignancies patients in Tianjin HI.
Eligibility Criteria
Inclusion
- 1\) Aged ≥ 18 years old. 2) Receiving hematopoietic stem cell transplantation; OR being diagnosed with hematological malignancies (including but not limited to leukemia, lymphoma, and multiple myeloma) and receiving chemotherapy.
- 3\) New onset of respiratory symptoms; OR exacerbation of existing chronic respiratory symptoms (such as previously diagnosed chronic runny nose, seasonal allergies, chronic lung disease, etc.).
- 4\) Willing to sign an informed consent form, able to understand and willing to follow the study protocol.
Exclusion
- Unwillingness to sign an informed consent form.
Key Trial Info
Start Date :
November 30 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 20 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06490549
Start Date
November 30 2023
End Date
June 20 2025
Last Update
July 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China